Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

To join this study, your doctor will need to check various things. You must have advanced breast cancer that is Hormone Receptor-positive (HR+) and HER2-negative (HER2-), and it should have spread to other parts of your body. Importantly, your cancer needs to have shown signs of getting worse, even after you've had at least two different hormone therapies for your advanced cancer. Or, if your cancer came back or worsened quickly after you started hormone therapy, you might also be able to join.

You also need to be well enough to receive chemotherapy treatments like capecitabine, nab-paclitaxel, or paclitaxel. The study will need a sample of your cancer tissue. If you have HIV, you can still participate if your HIV infection is well-controlled with medication. The medical team will carefully review all your medical details to see if this study is right for you.

If you decide to take part in this study, you will either receive the new medicine, Sacituzumab Govitecan, or one of the standard chemotherapy treatments (paclitaxel, nab-paclitaxel, or capecitabine). You won't get to choose which one you receive; it will be decided randomly. You will have regular visits to the clinic for your treatment and to have your health checked. These visits will involve physical examinations, blood tests, and scans (like CT or MRI scans) to see how your cancer is responding to the treatment. The number of visits and the total length of your participation will depend on how you respond to the treatment and how long the drug continues to help you. The study team will explain everything in detail, including what to expect at each appointment and how long the study might last for you.